Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V591 (COVID-19 Vaccine) in Healthy Younger and Older Participants
NCT04498247Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Aug 2020
- Primary completion
- Mar 2021
- Modality
- Viral Vector Vaccines
- Countries
- 3
01
Overview
A Phase 2 trial of V591 in coronavirus disease 2019 (COVID-19), sponsored by Merck & Co.. Started Aug 2020; status: terminated.
02
Drugs
V591
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04498247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04498247.